MOVER · TUE SEP 29 2026

Why SMMT rose 22.7% on Sep 29 2026: astrazeneca investment

SMMT+22.7%on Tue Sep 29 2026

Summit Therapeutics Inc. Common Stock was up 22.7% on the day at $19.00, ranked #5 on — its usual five-minute volume, when TapeRank recorded this spike at 04:01 ET during the pre-market session.

THE DAY ON THE LIST · 1 EVENT

04:01 ET
MOVER · PRE-MARKET
$19.00 · ▲ 22.7% ON THE DAY · — 5M RVOL · RANK #5
JUSTIFIEDCONFIDENCE5/5
Summit Therapeutics is up 24% after AstraZeneca agreed to invest $2 billion in newly issued equity and entered a clinical collaboration covering ivonescimab and sonesitatug vedotin. The large, quantified strategic investment is a substantial catalyst for a move of this size, while the newly issued shares create dilution risk.
WHYA 24% pre-market gain is proportionate to a $2 billion strategic equity investment plus clinical collaboration, though the issuance offsets part of the upside for existing holders.
ANALYZED 04:01 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNA
THE ROW AND SESSION LEVELS AT 04:01 ET
LAST19.00
DAY▲ 22.7%
5 MIN▼ 2.91%
5M RVOL—
5M $VOL$743K
FLOAT*797.7M
RANK#5
SESSIONPRE-MARKET
VWAP19.16
HOD19.57
LOD18.78
OR HIGH—
OR LOW—
PREV CLOSE15.48
PM HIGH19.57
PM LOW18.78
GAP▲ 22.74% (indicated)
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

THE SESSION

09:30 ETOpened at $18.91, +22.2% on the previous close of $15.48
09:30 ETRegular-session high, $19.09
10:47 ETRegular-session low, $16.15
15:59 ETLast trade of the regular session, $16.36, +5.7% on the previous close of $15.48
Volume: 23.9M shares in regular hours, 2.5M before the open

SMMT opened at $18.91 after rising 22.2% from the previous close and reached $19.09 early in the session. It then fell to $16.15 by 10:47 ET without any halts, before ending at $16.36, still 5.7% above the prior close. TapeRank’s read tied the initial move to AstraZeneca’s agreement to invest $2 billion in newly issued Summit equity and collaborate on developing ivonescimab and sonesitatug vedotin, while noting that the share issuance created dilution risk.

WRITTEN THU OCT 15 2026 17:58 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

MON 17:37 ETAstraZeneca Has Entered Into An Agreement To Invest $2B In Newly Issued Equity In Summit Therapeutics To Accelerate The Development Of Ivonescimab, A First-In-Class Bispecific Antibody Targeting PD-1 And VEGF, In Combination With Antibody Drug Conjugates Across Tumour Types; Summit And AstraZeneca Have Also Entered Into A Clinical Collaboration Agreement To Evaluate Sonesitatug Vedotin In Combination With IvonescimabBenzinga

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

ECGSURGING 0:05

79.71

▼ 29.3%

▼ 1.41%

41.0×

FAD

$6.2M

51.1M*

STRETCHED

CAVASURGING 0:00

64.78

▲ 7.4%

▲ 1.30%

9.3×

ORBHODVWH

$11.6M

116.8M*

UNEXPLAINED

URGNSURGING 0:00

29.16

▼ 15.2%

▼ 1.29%

15.6×

FAD

$1.4M

48.9M*

JUSTIFIED

MPTISURGING 0:00

64.15

▼ 1.5%

▲ 0.96%

23.8×

VWH

$637K

4.3M*

UNEXPLAINED

LSPDSURGING 0:00

11.52

▲ 4.9%

▼ 1.24%

16.5×

ORB

$426K

133.3M*

UNEXPLAINED

CRCTSURGING 0:00

8.90

▲ 49.2%

▼ 0.72%

15.1×

GAPORBVWHEXT

$395K

54.7M*

STRETCHED

BROSSURGING 0:00

43.97

▲ 0.9%

▼ 0.91%

4.0×

FAD

$4.3M

137.9M*

UNEXPLAINED

LMRICOOLING 1:35

12.85

▲ 14.5%

▲ 1.06%

132×

ORBHODVWH

$1.7M

—

UNEXPLAINED

Open the full list